Trial Information
Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab
Inclusion Criteria:
- Signed Informed Consent Form
- Enrollment in one of a list of certain randomized, controlled bevacizumab trials
Exclusion Criteria:
- Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)
- Congenital long QT syndrome
- Family history of long QT syndrome
- Clinically significant bradycardia (defined as < 50 beats/minute)
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Principal Investigator
Jane Huang, M.D.
Investigator Role:
Study Director
Investigator Affiliation:
Genentech
Authority:
United States: Food and Drug Administration
Study ID:
AVF4223g
NCT ID:
NCT00477425
Start Date:
June 2007
Completion Date:
Related Keywords:
- Carcinoma
- Avastin
- Carcinoma